Coalition for Global Hepatitis Elimination

blue

Coalition for Global Hepatitis Elimination

Virus targets
Hepatitis B
Hepatitis C
Type
Elimination
Operational research
Prevention implemention
Technical assistance
Testing and treatment implementation
Setting
Global
Other targets
HIV
Phase
Active
Health outcomes
Incidence
Mortality
Prevalence
WHO region
African Region
Eastern Mediterranean Region
European Region
Region of the Americas
South-East Asia Region
Country
Global
Key interventions
HBV perinatal screening and prophylaxis
HBV testing and linkage to care
HCV testing and linkage to Care
HCV treatment
Hep B birth-dose vaccination
Hepatitis B Vaccination
Implementation of birth dose vaccination
Persons who inject drugs: HCV cure as prevention
Persons who inject drugs: Medication assisted therapy
Persons who inject drugs: Syringe service program(s)
Screening of pregnant women
Strategic data analysis
Target population
Adults (> 19 years of age)
Children (> one year < 10 years of age)
Incarcerated populations (current and former)
Men who have sex with men
Newborn (born in last 30 days)
Persons who inject drugs
Performance target
Care cascade: HBV testing
Care cascade: HBV treatment
Care cascade: HCV testing
Care cascade: HCV treatment
Hepatitis B vaccination coverage
If you would like to have a program page for your program, please create an account and submit program information here

Summary and objectives

Globally, 328 million people are infected with the hepatitis B (HBV) and hepatitis C (HCV) viruses and millions of new infections occur annually. HBV and HCV cause 1.3 million deaths annually and are the leading cause of mortality from primary liver cancer - the fourth leading cause of cancer deaths globally. If left unchecked, by 2040, deaths from HBV and HCV will exceed the number of deaths from HIV, TB, and malaria combined. The burden of HBV and HCV varies with ~ 25 low and middle income countries (LMIC) shouldering over 75% of HBV and HCV-related deaths. With the availability of reliable tests, highly effective vaccines and curative therapies, the World Health Organization (WHO) has targeted hepatitis B and hepatitis C for elimination. National and sub-national elimination programs are in various stages of planning and implementation. However, public health and clinical data are often not available to guide program development.

Last updated